Should I buy Repligen (RGEN) stock or is it too late?
⭐ The most reliable of them, either direction: UBS — 64% of its targets hit on this sector (124 calls tested). It aims for $225 (+28 %), call made on September 10, 2026, maturing on September 10, 2027 (34 d ago).
Firm-by-firm track record on Repligen
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| Jefferies | 80 % | +69.3 % | 5 | $135 -23% |
| HC Wainwright & Co. | 58 % | +27.3 % | 12 | $208 +19% |
| JP Morgan | 25 % | +0.4 % | 8 | $175 +0% |
| RBC Capital | 20 % | -9.8 % | 10 | $204 +16% |
| Stifel | 86 % | +54.7 % | 7 | — |
| Stephens & Co. | 40 % | +10.5 % | 5 | — |
| SVB Leerink | 29 % | -1.2 % | 7 | — |
| Keybanc | 43 % | -5.4 % | 7 | — |
✅ Reasons to believe
- 89% of analysts rate it a buy (Buy consensus, 9 ratings) — a sign of market conviction.
⚠️ Reasons to hesitate
- Even the most reliable firm on RGEN, Evercore ISI Group (100% hit rate, 2 scored calls), only targets $160 (call made on July 6, 2026, maturing on July 6, 2027) (-9%) in its most recent call, and $170 (call made on February 25, 2026, maturing on February 25, 2027) (-3%) in the one coming due soonest. The stock may already have run past its target.
- The consensus is not unanimous: of 9 ratings, 1 is neutral.
- Limited upside: the median target is only +0% from the current price.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
- No dividend: your return depends only on price appreciation.
The analyst consensus on RGEN
Median target $175 (+0%) · 9 ratings · Buy consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in Repligen now?
We won't decide for you. The facts: 89% of analysts rate it a buy, median target $175 (+0%), and Evercore ISI Group (most reliable on RGEN, 100%) targets $160. Weigh that against valuation. This is not personalized advice.
Is it too late to invest in Repligen?
The stated upside is small: the median target ($175) sits just +0% from the price ($175) (most reliable on RGEN: Evercore ISI Group, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is Repligen still worth investing in?
It depends on the gap between the price ($175) and its estimated value: analysts target $175 on median (+0%), with 89% buys (most reliable on RGEN: Evercore ISI Group, 100%). Cross-check with their real reliability on RGEN and the cautions above. Information, not advice.
What's the main risk in buying RGEN?
Even the most reliable firm on RGEN, Evercore ISI Group (100% hit rate, 2 scored calls), only targets $160 (call made on July 6, 2026, maturing on July 6, 2027) (-9%) in its most recent call, and $170 (call made on February 25, 2026, maturing on February 25, 2027) (-3%) in the one coming due soonest. The stock may already have run past its target.
→ Go deeper: the full Repligen profile (consensus, analyst reliability, price target, performance).